Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

Leukemia Research

Volumn 35, Issue 1, 2011, Pages

  Valent, Jason N ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FUROSEMIDE;

BLOOD SMEAR; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LARGE GRANULAR LYMPHOCYTE; LETTER; LONGITUDINAL STUDY; LYMPHOCYTOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTOSIS; PREVALENCE; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES;

EID: 78650171874     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.022     Document Type: Letter

References (6)

1. Mustjoki S., Ekblom M., Arstila T.P., Dybedal I., Epling-Burnette P.K., Guilhot F., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23:1398-1405.
2. Kim D.H., Kamel-Reid S., Chang H., Sutherland R., Jung C.W., Kim H.-J., et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia positive chromosome leukemia. Haematologica 2009, 94(1):135-139.
3. Porkka K., Khoury H.J., Paquette R.L., Matloub Y., Sinha R., Cortes J.E. Dasatinib 100mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010, 116(2):377-386.
4. Kreutzman A., Juvonen V., Kairisto V., Ekblom M., Stenke L., Seggewiss R., et al. Mono/oligoclonal T- and NK- cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010, 116:772-782.
5. Blake S.J., Lyons A.B., Fraser C.K., Hayball J.D., Hughes T.P. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008, 111:4415-4416.
6. Rasheed W., Flaim B., Seymour J.F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009, 33:861-864.